RPSM
BCRX icon

Royalty Pharma Sub-Manager’s BioCryst Pharmaceuticals BCRX Stock Holding History

Royalty Pharma Sub-Manager’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,846,154
Closed -$36.6M – 5
2026
Q1 		$36.6M Hold
3,846,154
– – 21.19% 3
2025
Q4 		$30M Buy
+3,846,154
New +$27.8M 17.51% 4

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Royalty Pharma Sub-Manager's BCRX Position: Q2 2026 in Review

Royalty Pharma Sub-Manager sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 3,846,154 shares — an estimated $36.6M sold.

Royalty Pharma Sub-Manager first reported a position in BCRX in Q4 2025 and held it in 2 quarters. The position peaked at $36.6M in Q1 2026. 317 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Royalty Pharma Sub-Manager reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Royalty Pharma Sub-Manager sold 3,846,154 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $36.6M.
  • Royalty Pharma Sub-Manager first reported a position in BioCryst Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Royalty Pharma Sub-Manager's BioCryst Pharmaceuticals position peaked at $36.6M in Q1 2026.
  • 317 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Royalty Pharma Sub-Manager's 13F filing for Q2 2026, filed 14 Aug 2026.